WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On May10, 2017, WAVE Life Sciences Ltd. (the Company) announced
its financial results for the quarter ended March31, 2017. The
full text of the press release issued in connection with the
announcement is furnished as Exhibit 99.1 to this Current Report
on Form 8-K and is
incorporated by reference herein.
The information in
this Current Report on Form 8-K, including Exhibit 99.1
attached hereto, is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit relating
to Item 2.02 of this Current Report on Form 8-Kshall be deemed to
be furnishedand not filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press release issued on May10, 2017 |
About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)
WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb. WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Recent Trading Information
WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) closed its last trading session 00.00 at 20.85 with 38,751 shares trading hands.
